BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) went down by -9.59% from its latest closing price compared to the recent 1-year high of $131.95. The company’s stock price has collected -5.86% of loss in the last five trading sessions. Barron’s reported 13 hours ago that BioMarin’s Study of Its Hemophilia Gene-Therapy Looked Good
Is It Worth Investing in BioMarin Pharmaceutical Inc. (NASDAQ :BMRN) Right Now?
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) scored a price-to-earnings ratio above its average ratio, recording 18.78 x from its present earnings ratio. Plus, the 36-month beta value for BMRN is at 0.57. Opinions of the stock are interesting as 12 analysts out of 23 who provided ratings for BioMarin Pharmaceutical Inc. declared the stock was a “buy,” while 2 rated the stock as “overweight,” 9 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $110.85, which is $28.91 above the current price. BMRN currently public float of 180.42M and currently shorts hold a 6.50% ratio of that float. Today, the average trading volume of BMRN was 1.42M shares.
BMRN’s Market Performance
BMRN stocks went down by -5.86% for the week, with a monthly jump of 6.67% and a quarterly performance of 3.03%, while its annual performance rate touched -10.82%. The volatility ratio for the week stands at 3.86% while the volatility levels for the past 30 days are set at 3.55% for BioMarin Pharmaceutical Inc.. The simple moving average for the period of the last 20 days is -6.36% for BMRN stocks with a simple moving average of -12.55% for the last 200 days.
Analysts’ Opinion of BMRN
Citigroup, on the other hand, stated in their research note that they expect to see BMRN reach a price target of $86, previously predicting the price at $148. The rating they have provided for BMRN stocks is “Neutral” according to the report published on August 20th, 2020.
Stifel gave a rating of “Hold” to BMRN, setting the target price at $100 in the report published on August 19th of the previous year.
BMRN Trading at 0.62% from the 50-Day Moving Average
After a stumble in the market that brought BMRN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -38.43% of loss for the given period.
Volatility was left at 3.55%, however, over the last 30 days, the volatility rate increased by 3.86%, as shares surge +4.48% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +9.21% upper at present.
During the last 5 trading sessions, BMRN fell by -5.86%, which changed the moving average for the period of 200-days by -1.69% in comparison to the 20-day moving average, which settled at $86.93. In addition, BioMarin Pharmaceutical Inc. saw -7.36% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at BMRN starting from BIENAIME JEAN JACQUES, who sale 1,500 shares at the price of $88.18 back on Dec 29. After this action, BIENAIME JEAN JACQUES now owns 295,552 shares of BioMarin Pharmaceutical Inc., valued at $132,270 using the latest closing price.
BIENAIME JEAN JACQUES, the Chief Executive Officer of BioMarin Pharmaceutical Inc., sale 1,500 shares at $88.77 during a trade that took place back on Dec 28, which means that BIENAIME JEAN JACQUES is holding 297,052 shares at $133,155 based on the most recent closing price.
Stock Fundamentals for BMRN
Current profitability levels for the company are sitting at:
- -6.75 for the present operating margin
- +75.51 for the gross margin
The net margin for BioMarin Pharmaceutical Inc. stands at -1.41. The total capital return value is set at -2.91, while invested capital returns managed to touch -0.64. Equity return is now at value 25.00, with 16.30 for asset returns.
Based on BioMarin Pharmaceutical Inc. (BMRN), the company’s capital structure generated 29.13 points at debt to equity in total, while total debt to capital is 22.56. Total debt to assets is 19.39, with long-term debt to equity ratio resting at 17.20. Finally, the long-term debt to capital ratio is 13.32.
When we switch over and look at the enterprise to sales, we see a ratio of 9.07, with the company’s debt to enterprise value settled at 0.06. The receivables turnover for the company is 4.68 and the total asset turnover is 0.37. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.08.